Avoid common mistakes on your manuscript.
Dear Editor,
In 2019, a zoonotic coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the causative agent of Coronavirus Disease 2019 (COVID-19). As of 8 June 2020, the World Health Organization (WHO) has reported 6,912,751 globally confirmed cases with 400,469 deaths.
Although generally causes mild disease, SARS-CoV-2 infection can result in serious outcomes, including acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), the leading cause of mortality in patients with comorbidities. Recent autopsy studies of COVID-19 patients revealed mononuclear infiltration and excessive production of mucus in the infected lung, especially in the damaged small airways and alveoli (Bian and Team, 2020; Liu et al., 2020). This finding is a critical warning for clinical treatment, as if the mucus accumulation not dissolved, oxygen alone may not be able to achieve the goal for necessary breathing. Currently, no vaccines or specific anti-viral drugs have been approved for SARS-CoV-2, meriting the urgent development of novel therapies.
Thick mucus from coughs is a major clinical and pathological feature of COVID-19 and one of the most frequent symptoms in severe cases. Mucus plays a vital role in protecting the lungs against inhaled environmental injurious substances. The mucus-entrapped foreign materials are necessarily removed from the airways via the aid of coordinated ciliary beating or mucociliary clearance (MCC) (Fahy and Dickey, 2010). Conversely, in muco-obstructive airway disease, mucus becomes pathologic. Mucin hypersecretion and altered mucin macromolecular organization form a dysfunctional mucus gel (Fahy and Dickey, 2010). As a consequence, mucus accumulated in airways obstructs the respiratory tract lumen and limits airflow. Mucus accumulation can also cause by ciliary dysfunction, which has been observed in many diseases, including primary ciliary dyskinesia (PCD), cystic fibrosis (CF), asthma, chronic obstructive pulmonary disease (COPD), SARS-CoV, MERS-CoV and influenza virus infection (Tilley et al., 2015; Bustamante-Marin and Ostrowski, 2017; Fong, 2017; Chen et al., 2019).
At present, the disease pathogenesis of mucus hypersecretion leads ARDS in COVID-19 remains largely unknown. Here, we report the leukocytes and epithelial cells in the bronchoalveolar lavage fluid (BALF) from 3 severe COVID-19 patients (Table S1) at single-cell resolution and investigate the SARS-CoV-2 infection-induced ARDS at the cellular and molecular levels.
We performed single-cell RNA sequencing (scRNA-seq) based on the 10X genomics platform, passing through a rigorous quality-control process, the transcriptome profiles of 8,356 cells were subjected to downstream analysis. Firstly, we repurposed and integrated a public pulmonary scRNA-seq dataset (Reyfman et al., 2019) from 8 healthy donors as control, denoted HC Most cell types were consistent among the COVID-19 and HC samples, including macrophages, B cells, endothelial cells, ciliated cells, club cells, as well as type1 and type2 alveolar cells (AT1 and AT2) (Figs. 1A, 1B and S1A). Then we examined the involved cell type of SARS-COV-2 infection, we detected 23 cells with at least 2 viral mRNA reads (Fig. S1B), but containing minimal numbers of expressed genes (Fig. S1C), indicating that SARS-CoV-2 suppresses host gene expression. It is difficult to define the cell types according to such low coverage of expressed genes. Thus, we tested self-organizing map (SOM), linear support vector machine (SVM), and random forest (RF) for cell type prediction, RF perform best in our test data with the known cell identities (Fig. S1D). Thus, we build an RF based classifier (Fig. S1E) and unveiled monocytes/neutrophils and club cells as potential viral targets (Fig. S1F).
Next, we compared the differential expressing genes (DEGs) of each cell type between HC and COVID-19. MUC5AC is the major component of secreted mucins in the airways (Lillehoj et al., 2013; Krishn et al., 2018). Our analysis revealed a significant elevation of MUC5AC expression in patients, specifically in the club cells (Fig. 1C), suggesting club cells are predominant for mucins secretion post-infection. Our analysis revealed upregulation of additional mucin genes including the gel-forming mucins (GFM), MUC5AC and MUC5B, as well as membrane-tethered mucins, MUC4, MUC16 and MUC20 (Lillehoj et al., 2013) in patients’ club cells (Fig. 1D and 1E), and these observations were consistent across all patients (Fig. S1G). Meanwhile, TFF3 and TGM2, which can mediate cross-links between GFM fibers to form supramolecular assembly by isopeptide bonds, which will increase mucus viscosity and impairs MCC (Demouveaux et al., 2018), were also significantly increased in COVID-19 patients (Fig. 1D and 1E). Gene ontology (GO) analysis further demonstrated the COVID-19-specific enrichment of stimulatory C-type lectin receptor, response to IL-1 and TNF, hypoxia, as well as macrophage chemotaxis (Fig. 1F). Specifically, IL-1β and TNF-α were known to induce mucin production in surface epithelial cells (Krishn et al., 2018), illustrating the involvement of immune regulators. In contrast, the homeostasis and epithelial tube morphogenesis related genes were downregulated (Figs. 1F and S1H), suggesting lung damage in COVID-19. To understand the molecular basis, we enriched potential upstream transcription factors (TF) based on the DEGs of club cells, and results revealed 6 potential TF families were enriched in COVID-19 patients (Fig. 1G), including activator protein-1 (AP-1) and NFKB, which are known involved in IL-1β and TNF-α induced MUC5AC promoter activation respectively (Krishn et al., 2018). Taken together, these results demonstrated that COVID-19-stimulated mucin secretion in the club cells, potentially through the innate immune regulators, IL-1β and TNF-α, and leading to ARDS.
Furthermore, our results unveiled the master regulators for cilia generation, including FOXJ1 and RFX3 (Bustamante-Marin and Ostrowski, 2017), which were significantly down-regulated upon viral infection (Figs. 1H, 1I, and S2A). The expression of NEK10, the cilia-specific kinase whose activity promotes ciliary length and mucociliary transport (Chivukula et al., 2020), also dropped (Figs. 1H, 1I, and S2A). Besides, we noted the dampened transcription of ciliary structural (i.e., DNAI2, DNAF1, SPAG16, INTU, and AHI) and functional (i.e., IFT27) genes (Figs. 1H, 1I and S2A) (Bustamante-Marin and Ostrowski, 2017). Conversely, the ATP syntheses (e.g., ATP5F1E, ATP5MC2, and ATP5MG) were dramatically increased in COVID-19 patients (Figs. 1I and S2B). It is worth noting that, upon stimulation by high levels of extracellular ATP, the coordinate ciliary beat frequency disrupt and airway mucin secretion can be increased thousands-fold (Fahy and Dickey, 2010; Bustamante-Marin and Ostrowski, 2017). GO analysis again highlighted reduced ciliary maintenance and increased ATP synthesis pathways upon infection (Fig. 1J). Above all, these data demonstrated ciliary dysfunction post-SARS-CoV-2 infection.
Next, we assessed the contribution of AT1 and AT2 cells in COVID-19. The keratinization-related genes, including CSTA and KRT13, were significantly up-regulated (Fig. S2C–F). While four critical surfactant proteins (SPs)—SP-A, SP-B, SP-C, and SP-D, known to maintain the structural integrity of alveoli and facilitate gas exchange, were dramatically down-regulated in COVID-19 disease (Fig. S2C–E and S2G). Besides, the level of NKX2-1, the transcription factor required for surfactant synthesis was also reduced (Fig. S2H), indicating the loss of alveoli integrity and the possible pathogenesis of respiratory distress syndrome in COVID-19.
To evaluate the impact of the immune microenvironment on epithelial dysfunction upon viral infection, we dissected the transcriptomic profiles of three major regulators of innate immunity, monocytes, neutrophils, and macrophages. Increased levels of generalized inflammatory chemokines, including CCL2, CXCL8, CCL3, CCL4, CXCL2, CCL3L1, IL1RN, and IL1B, as well as the anti-viral restriction factor, IFITM3, were observed amongst the COVID-19 patients (Figs. 2A–E, S3A and S3B), reflecting exacerbated inflammatory response post-infection. Moreover, CCL2 was specifically elevated in the patients’ macrophages (Fig. 2E), possibly inducing the recruitment of inflammatory monocytes/neutrophils to the infection sites (Qian et al., 2011). Consistently, GO analysis demonstrated the enrichment of interferon and interleukin-associated pathways in the COVID-19-infected monocytes and neutrophils (Fig. S3C), highlighting the escalated innate immune defense upon infection. In the study of Liao et al. (2020), proinflammatory macrophages expressed FCN1 were found abundant in BALF from patients with severe COVID-19. However, we noticed only a mild increase of FCN1+ macrophages but significantly decreased FCN1+ monocytes/neutrophils in COVID-19 patients (Figs. 2F and S3D), indicating the distinct immune profiles among COVID-19 patients.
To further scrutinize the immune features of the innate immune players, we depicted the cell fate trajectory of monocyte, neutrophil, and macrophage subtypes (Fig. S3E). Notably, MIP-1 chemokines, CCL3 (MIP-1α) and CCL4 (MIP-1β), as well as MIP-1-induced proinflammatory cytokines, IL-1β and TNF distributed among monocyte and neutrophil subgroup 2 cells (Fig. S3E–G), demonstrating their potency in the inflammatory response as well as the potential impairment of airway epithelial function and MCC.
To investigate the consequence of monocyte and neutrophil activation, we analyzed the differentially expressed genes of the NK and T cell populations in both healthy and COVID-19 individuals (Fig. S3H). Notably, antigen processing pathways were up-regulated (Fig. S3I), whereas lost IL-7R and IL-2 expressions (Fig. S3J), indicating the hindered T cell survival.
SARS-CoV-2, the causative pathogen of COVID-19 pneumonia, has spread worldwide. The clinical symptoms of COVID-19 vary from asymptomatic to severe ARDS. Currently, no approved anti-viral drug, vaccine, or effective clinical treatment for COVID-19 due to the lack of understanding of disease pathogenies. Here we comprehensively dissected the epithelial and immune profiles of BALF derived from severe COVID-19 patients at a single-cell level. Specifically, monocytes/neutrophils driven pulmonary epithelial dysfunction upon viral infection was characterized in molecular details, revealing high-inflammation and mucin hypersecretion of the infected respiratory tract. The exacerbated inflammatory response was observed post-infection, featured by the drastic elevation of IL-1β, the activators of mucin production. Further, mucin hypersecretion was primarily detected in the club cells of the patients, highlighting the major source of mucus in COVID-19 disease. Besides, deficiency of ciliary structural components and dysregulation of ATP production were uncovered in the patients’ cilia, demonstrating ciliary dysfunction and impaired mucus removal machinery. In turn, mucus build-up would disseminate infection and amplify inflammation, leading to ALI and ARDS (Fig. 2G). Overall, our results revealed monocytes/neutrophils-released pro-inflammation cytokines, IL-1β as the major driving force towards airway epithelial dysregulation and ARDS in severe COVID-19 patients.
Rapid onset of widespread inflammation in the lungs leads to ARDS and subsequent fatality in COVID-19. To reveal the mechanism bridging exacerbated immune response and ARDS, our study provided solid evidence from various perspectives of epithelial dysfunction, encompassing club cell-driven hyper-production of mucins, dysrhythmic ciliary movement, and compromised alveoli integrity. However, mucin hypersecretion and altered mucin macromolecular organization form a dysfunctional mucus gel, which is difficult to be removed by drugs or sputum aspirator, highlighting the clinical value of removing the mucins at the earlier stage. At the molecular level, our results revealed these malfunctioned biological processes had been tightly associated with IL-1β induced inflammatory microenvironment. Notably, recently a retrospective cohort study reported that treatment with high-dose anakinra, an IL-1 receptor antagonist, was safe and associated with clinical improvement in 72% COVID-19 patients (Cavalli et al., 2020). Highlighted blocking IL-1β holds significant translational value.
Liao et al. (2020) have surveyed the BALF immune response in COVID-19 patients and only focused on the immune cells like macrophage and CD8+ T cells. In contrast, our study takes a significant analysis of lung epithelial cells. It reveals mucin hypersecretion and ciliary dysfunction in severe COVID-19 patients, which would lead to acute lung injury and ARDS. Furthermore, our study revealed the highly activated monocytes and neutrophils, instead of macrophages, were the source of the exacerbated immune response characterized by increased IL1β.
Taken together, our investigation provides pathological and mechanistic insights of ARDS in severe COVID-19 patients and provided translational insights towards the treatment of severe COVID-19 cases.
References
Bian X-W, Team TC-P (2020) Autopsy of COVID-19 victims in China. National Science Review.
Bustamante-Marin XM, Ostrowski LE (2017) Cilia and mucociliary clearance. Cold Spring Harb Perspect Biol 9:28241
Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Tassan Din C, Boffini N et al (2020) Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2:e325–e331
Chen AJ, Dong J, Yuan XH, Bo H, Li SZ, Wang C, Duan ZJ, Zheng LS (2019) Anti-H7N9 avian influenza A virus activity of interferon in pseudostratified human airway epithelium cell cultures. Virol J 16:44
Chivukula RR, Montoro DT, Leung HM, Yang J, Shamseldin HE, Taylor MS, Dougherty GW, Zariwala MA, Carson J, Daniels MLA et al (2020) A human ciliopathy reveals essential functions for NEK10 in airway mucociliary clearance. Nat Med 26:244–251
Demouveaux B, Gouyer V, Gottrand F, Narita T, Desseyn JL (2018) Gel-forming mucin interactome drives mucus viscoelasticity. Adv Colloid Interface Sci 252:69–82
Fahy JV, Dickey BF (2010) Airway mucus function and dysfunction. N Engl J Med 363:2233–2247
Fong IW (2017) Emerging animal coronaviruses: first SARS and now MERS. In: Emerging zoonoses, pp 63–80.
Krishn SR, Ganguly K, Kaur S, Batra SK (2018) Ramifications of secreted mucin MUC5AC in malignant journey: a holistic view. Carcinogenesis 39:633–651
Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, Wang F et al (2020) Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med
Lillehoj EP, Kato K, Lu W, Kim KC (2013) Cellular and molecular biology of airway mucins. Int Rev Cell Mol Biol 303:139–202
Liu Q, Wang RS, Qu GQ, Wang YY, Liu P, Zhu YZ, Fei G, Ren L, Zhou YW, Liu L (2020) Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi 36:21–23
Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475:222–225
Reyfman PA, Walter JM, Joshi N, Anekalla KR, McQuattie-Pimentel AC, Chiu S, Fernandez R, Akbarpour M, Chen CI, Ren Z et al (2019) Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis. Am J Respir Crit Care Med 199:1517–1536
Tilley AE, Walters MS, Shaykhiev R, Crystal RG (2015) Cilia dysfunction in lung disease. Annu Rev Physiol 77:379–406
Footnotes
We thank the patient who took part in this study. This work was supported by the National Key R&D Program of China (and 2018YFA0507200), the special project for COVID-19 of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2020GZR110106006) and the emergency grants for prevention and control of SARS-CoV-2 of Guangdong province (2020B111108001). This work was supported by Science and Technology Planning Project of Guangdong Province, China (2017B030314056).
J.C., X.D. and X.C. conceived and supervised the study. S.C., B.C., A.Z., H.H., D.L., Y.L., J.P., X.M., X.H., F.Y., J.Z., N.Z. collected clinical specimen. J.H., H.F., L.L., Y.M., J.S., Y.W., Y.Z., H.L., S.C., J.W. did the single-cell sequencing and data analysis. J.H., J.W. and J.C. wrote the manuscript.
Jiangping He, Shuijiang Cai, Huijian Feng, Baomei Cai, Lihui Lin, Yuanbang Mai, Yinqiang Fan, Airu Zhu, Huang Huang, Junjie Shi, Dingxin Li, Yuanjie Wei, Yueping Li, Yingying Zhao, Yuejun Pan, He Liu, Xiaoneng Mo, Xi He, Shangtao Cao, FengYu Hu, Jincun Zhao, Jie Wang, Nanshan Zhong, Xinwen Chen, Xilong Deng and Jiekai Chen declare that they have no conflict of interest. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000(5). Informed consent was obtained from all patients for being included in the study. All scRNA-seq data used in this study can be accessed in GEO under the accession number GSE147143.
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
He, J., Cai, S., Feng, H. et al. Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients. Protein Cell 11, 680–687 (2020). https://doi.org/10.1007/s13238-020-00752-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13238-020-00752-4